Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MoST substudy of palbociclib priming followed by palbociclib + avelumab in molecularly selected advanced cancers
ACTRN12620000568910Phase 2Completed
- Sponsor
- The University of Sydney
- Start
- May 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib and avelumab in cancer, Nonhematologic neoplasms and hematopoietic malignancies, sponsored by The University of Sydney. Primary endpoint: Progression-free survival at 6 months. Started May 2021; status: completed.
02
Drugs
palbociclibavelumab
03
Conditions
cancerNonhematologic neoplasmshematopoietic malignancies
Beyond the preview
Go deeper on ACTRN12620000568910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000568910.